文献速递认知障碍与痴呆

临床正常老年人中体力活动与β淀粉样蛋白对纵向认知和神经退行性变的关联

Associations of Physical Activity and β-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults.
PubMed 文献 · JAMA Neurol · 2019-01-01

该纵向观察研究纳入182名临床正常的老年人,发现较高体力活动可减弱β淀粉样蛋白负荷与认知下降和脑体积丢失的负相关,且该关联独立于血管风险;较低血管风险也独立减缓Aβ相关认知下降和体积丢失。

要点

  • 较高体力活动与较慢的Aβ相关认知下降和脑体积丢失相关。
  • 较低血管风险独立与较慢的Aβ相关认知下降和体积丢失相关。
  • 体力活动和降低血管风险可能对延缓阿尔茨海默病进展有附加保护作用。

核心结论

  • 较高体力活动和较低血管风险独立减弱Aβ负荷与认知下降和神经退行性变的负相关。

研究设计与样本

  • 纵向观察研究纳入182名临床正常老年人,来自哈佛老龄脑研究,收集2010年4月至2018年6月数据。

主要发现

  • 体力活动与Aβ负荷交互作用显著:较高体力活动与较慢Aβ相关认知下降相关(β=0.03,95%CI 0.02-0.05,P<.001)。
  • 体力活动与Aβ负荷交互作用显著:较高体力活动与较慢Aβ相关体积丢失相关(β=482.07,95%CI 189.40-774.74,P=.002)。
  • 较低血管风险独立与较慢Aβ相关认知下降相关(β=-0.04,95%CI -0.06至-0.02,P<.001)。
  • 较低血管风险独立与较慢Aβ相关体积丢失相关(β=-483.41,95%CI -855.63至-111.20,P=.01)。

临床怎么用

  • 在临床正常的老年人中,鼓励体力活动和降低血管风险可能有助于延缓Aβ相关认知下降和神经退行性变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In the absence of disease-modifying therapies for Alzheimer disease, there is a critical need to identify modifiable risk factors that may delay the progression of Alzheimer disease. OBJECTIVE: To examine whether physical activity moderates the association of β-amyloid (Aβ) burden with longitudinal cognitive decline and neurodegeneration in clinically normal individuals and to examine whether these associations are independent of vascular risk. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal observational study included clinically normal participants from the Harvard Aging Brain Study. Participants were required to have baseline Aβ positron emission tomography data, baseline medical data to quantify vascular risk, and longitudinal neuropsychological and structural magnetic resonance imaging data. Data were collected from April 2010 to June 2018. Data were analyzed from August to December 2018. MAIN OUTCOMES AND MEASURES: Baseline physical activity was quantified with a pedometer (mean steps per day). Baseline Aβ burden was measured with carbon 11-labeled Pittsburgh Compound B positron emission tomography. Cognition was measured annually with the Preclinical Alzheimer Cognitive Composite (PACC; median [interquartile range] follow-up, 6.0 [4.3-6.3] years). Neurodegeneration was assessed with longitudinal structural magnetic resonance imaging (2 to 5 scans per participant; median [interquartile range] follow-up, 4.5 [3.0-5.0] years), with a focus on total gray matter volume and regional cortical thickness. Physical activity and Aβ burden were examined as interactive predictors of PACC decline and volume loss in separate linear mixed models, adjusting for age, sex, education, apolipoprotein E ε4 status, and, where appropriate, intracranial volume. Secondary models adjusted for vascular risk and its interaction with Aβ burden. RESULTS: Of the 182 included participants, 103 (56.6%) were female, and the mean (SD) age was 73.4 (6.2) years. In models examining PACC decline and volume loss, there was a significant interaction of physical activity with Aβ burden, such that greater physical activity was associated with slower Aβ-related cognitive decline (β, 0.03; 95% CI, 0.02-0.05; P < .001) and volume loss (β, 482.07; 95% CI, 189.40-774.74; P = .002). Adjusting for vascular risk did not alter these associations. In these models, lower vascular risk was independently associated with slower Aβ-related PACC decline (β, -0.04; 95% CI, -0.06 to -0.02; P < .001) and volume loss (β, -483.41; 95% CI, -855.63 to -111.20; P = .01). CONCLUSIONS AND RELEVANCE: Greater physical activity and lower vascular risk independently attenuated the negative association of Aβ burden with cognitive decline and neurodegeneration in asymptomatic individuals. These findings suggest that engaging in physical activity and lowering vascular risk may have additive protective effects on delaying the progression of Alzheimer disease.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Rabin JS, Klein H, Kirn DR, et al. Associations of Physical Activity and β-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. JAMA Neurol. 2019. PMID: 31312836. doi:10.1001/jamaneurol.2019.1879

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。